Semax
Heptapeptide derived from ACTH (4-10)
Neuromodulator with mostly preclinical evidence outside Russia.
Back to technical sheets- Class
- Heptapeptide derived from ACTH (4-10)
- Also known as
- Clinical use in Russia; limited Western evidence
Mechanism of action
Derived from an ACTH fragment without corticotropic hormonal activity. Proposed neuromodulatory and nootropic effects are attributed to it, with possible influence on neurotrophic factors (BDNF).
Evidence
Used clinically in Russia; elsewhere the evidence is limited and mostly preclinical. Not approved in most countries.
Studied uses
- Neurological/cognitive contexts (regional use; limited evidence)
Safety considerations
- Limited clinical evidence outside its region of use
- Not approved in most jurisdictions
- Poorly characterized long-term safety profile
Batch quality data
We publish these figures because they are the ones the program itself teaches you to ask for.
- Purity
- ≥ 98 % (HPLC)
- Net content
- 83 %
- Batch
- SMX-2601
- Presentation
- Polvo liofilizado en vial sellado
Net content is the fraction of the vial’s weight that is actually peptide, after discounting water, salts and excipients. It is the figure to calculate with, not the label weight.
Sample prices and batch data while the real ones are loaded.
Educational reference sheet. It is not a recommendation to use, a clinical indication or a protocol. Many of these compounds are marketed for research use only and are not approved for human use. Always cross-check with the primary literature and the regulation in your country.